SCHEMBL15425990

SCHEMBL15425990

COc1ccc(S(=O)(=O)N2CCC3(CC2)OCCN3S(=O)(=O)c2ccc(CO)cc2)cc1

nearest known ligand 0.83

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 2/20 0.67
▸ NPC1 O15118 1/20 0.50
▸ PKM P14618 1/20 0.50
▸ PKLR P30613 1/20 0.50
▸ RAB9A P51151 1/20 0.50
▸ ALDH1A1 P00352 4/20 0.48
▸ HSD17B10 Q99714 2/20 0.48
▸ KDM4E B2RXH2 1/20 0.48
▸ USP2 O75604 1/20 0.48
▸ HTT P42858 2/20 0.47
▸ LMNA P02545 2/20 0.47
▸ POLB P06746 2/20 0.47
▸ MEN1 O00255 1/20 0.47
▸ TSHR P16473 1/20 0.47
▸ KMT2A Q03164 1/20 0.47
▸ MAPK1 P28482 1/20 0.47
▸ SMN1; SMN2 Q16637 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12621923 0.91 L3MBTL1 (0.78) L3MBTL1NPC1PKMPKLRRAB9A
SCHEMBL12626093 0.87 L3MBTL1 (0.54) L3MBTL1USP2HTTLMNAPOLB
SCHEMBL12622095 0.86 L3MBTL1 (0.68) L3MBTL1NPC1PKMPKLRRAB9A
SCHEMBL12621865 0.86 L3MBTL1 (0.68) L3MBTL1NPC1PKMPKLRRAB9A
SCHEMBL25493754 0.86 L3MBTL1 (0.52) L3MBTL1PKMALDH1A1USP2HTT
SCHEMBL12626207 0.84 L3MBTL1 (0.61) L3MBTL1ALDH1A1LMNAPOLBMAPK1
SCHEMBL25493808 0.83 L3MBTL1 (0.53) L3MBTL1ALDH1A1USP2SMN1; SMN2
SCHEMBL12623925 0.82 L3MBTL1 (0.67) L3MBTL1NPC1PKMPKLRRAB9A
SCHEMBL12623954 0.81 L3MBTL1 (0.64) L3MBTL1NPC1PKMPKLRRAB9A
SCHEMBL18133264 0.81 L3MBTL1 (0.66) L3MBTL1NPC1PKMPKLRRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10017736-B2 Method of inhibiting tau phosphorylation PAIN THERAPEUTICS, INC. (US) 2018-07-10 — — US disclosed
US-9500640-B2 Alzheimer's disease assay in a living patient PAIN THERAPEUTICS, INC. (US) 2016-11-22 — — US disclosed
US-9433604-B2 Method for inhibiting growth of cancer cells PAIN THERAPEUTICS INC. (US) 2016-09-06 — — US disclosed
US-9354223-B2 Alzheimer's disease assay in a living patient PAIN THERAPEUTICS INC. (US) 2016-05-31 — — US disclosed
US-20150148318-A1 METHOD FOR INHIBITING GROWTH OF CANCER CELLS PAIN THERAPEUTICS, INC. 2015-05-28 — — US disclosed
US-20140017699-A1 ALZHEIMER'S DISEASE ASSAY IN A LIVING PATIENT CASSAVA SCIENCES, INC. 2014-01-16 — — US disclosed
US-20140018341-A1 METHOD OF INHIBITING TAU PHOSPHORYLATION CASSAVA SCIENCES, INC. 2014-01-16 — — US disclosed
US-20140017698-A1 ALZHEIMER'S DISEASE ASSAY IN A LIVING PATIENT WANG HOAU-YAN (US) 2014-01-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140018341-A1 METHOD OF INHIBITING TAU PHOSPHORYLATION FLNA, FLNB, MAPT L3MBTL1 1789/4885NPC1 2309/4885PKM 2983/4885
US-10017736-B2 Method of inhibiting tau phosphorylation FLNA, FLNB, MAPT L3MBTL1 1789/4885NPC1 2309/4885PKM 2983/4885
US-20150148318-A1 METHOD FOR INHIBITING GROWTH OF CANCER CELLS FLNA, FLNB, FSCN1 L3MBTL1 1041/4885NPC1 1832/4885PKM 3666/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback